Immunosurveillance, Immunodeficiencies and Lymphoproliferations: Lymphoproliferative Disorders in Congenital and Acquired Immunodeficiencies

ISBN-13: 9783540422822 / Angielski / Twarda / 2001 / 158 str.

S. H. Oertel; H. Riess; S. H. Oertel

Opis

It has been discovered that various diseases or therapeutic modalities that induce a state of immunosuppression may cause virally driven lymphoproliferations. This book summarizes this group of immunodeficiency-associated lymphoproliferations.

Spis treści

Immunosurveillance, Immunodeficiency and Lymphoproliferations.- Clinicopathological Characteristics of Post-Transplant Lymphoproliferative Disorders.- Latrogenic Lymphoproliferative Disorders in Non-Transplantation Settings.- The Role of Kaposi’s Sarcoma-Associated Herpesvirus (KSHV/HHV-8) in Lymphoproliferative Diseases.- Dendritic Cells for the Induction of EBV Immunity.- NF-?B Inhibition in EBV-Transformed Lymphoblastoid Cell Lines.- Epstein-Barr Viral Load as a Tool to Diagnose and Monitor Post-Transplant Lymphoproliferative Disease.- The Role of Immunosuppression in Lymphoma.- Indentification of Prognostic Factors in Post-Transplant Lymphoproliferative Disorders.- Methods and Objectives of a Large US Multicenter Case-Control Study of Post-Transplant Lymphoproliferative Disorder in Renal Transplant Patients.- Antiviral Treatment of Epstein-Barr Virus-Associated Lymphoproliferations.- Low-Dose Chemotherapy for Children with Post-Transplant Lymphoproliferative Disease.- Engineered Antibody for Treating Lymphoma.- Treatment of Post-Transplant Lymphomas with Anti-B-Cell Monoclonal Antibodies.- Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes for the Prevention and Treatment of EBV-Associated Post-Transplant Lymphomas.- Non-Myeloablative Stem Cell Transplantation for Congenital Immunodeficiencies.- Prognostic Factors in the Treatment of Human Immunodeficiency Virus-Associated Non-Hodgkin’s Lymphoma.- Infusional CDE with Rituximab for the Treatment of Human Immunodeficiency Virus-Associated Non-Hodgkin’s Lymphoma: Preliminary Results of a Phase I/II Study.